Analysis: Healthcare companies counter investor worries over Wegovy effect

  • 📰 Reuters
  • ⏱ Reading Time:
  • 47 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 22%
  • Publisher: 97%

Australia News News

Australia Australia Latest News,Australia Australia Headlines

Healthcare companies who profit from treating obese and overweight patients are trying to convince investors that powerful new weight-loss drugs won't shrink their businesses.

The global market for obesity drugs could reach as much as $100 billion within a decade due to the effectiveness of Novo Nordisk's

"The market is in a shoot-first, ask-questions-later mood when it comes to weight-loss drugs," said Nicholas Anderson, manager of the Thornburg International Growth Fund, which holds shares of Novo Nordisk. "What's less clear on the losers side is who will actually be affected and how long will it take to show up in numbers.

"We expect it will take at least a decade to reach peak penetration of these products in the indicated population," Kenneth Stein, Boston Scientific's global chief medical officer, told investors on Thursday, adding that only a minority of obese American patients will use the drugs.

The weight-loss drugs' cost and uncertainty about whether their use will improve the long-term health of patients and reduce healthcare spending will limit near-term expansion of insurance coverage, said Ann Hynes, a healthcare services analyst at Mizuho Securities.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in AU

Australia Australia Latest News, Australia Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Analysis-Healthcare companies counter investor worries over Wegovy effectAnalysis-Healthcare companies counter investor worries over Wegovy effect
Source: Investingcom - 🏆 450. / 53 Read more »

Nearly 500 jobs lost following healthcare company closing in OpelikaBaxter is an American Multinational Healthcare company. They primarily focus on products to treat kidney disease, like renal filters for dialysis. Formally known as Gambro, they chose to settle in Opelika back in 2005, investing $165 million into their facility.
Source: wsfa12news - 🏆 338. / 59 Read more »